Atrial Fibrillation - Pipeline Review, H2 2016

Date: August 10, 2016
Pages: 97
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AD7F669709AEN
Leaflet:

Download PDF Leaflet

Atrial Fibrillation - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Atrial Fibrillation - Pipeline Review, H2 2016’, provides an overview of the Atrial Fibrillation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation
  • The report reviews pipeline therapeutics for Atrial Fibrillation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Atrial Fibrillation therapeutics and enlists all their major and minor projects
  • The report assesses Atrial Fibrillation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Atrial Fibrillation
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Atrial Fibrillation Overview
Therapeutics Development
Pipeline Products for Atrial Fibrillation - Overview
Pipeline Products for Atrial Fibrillation - Comparative Analysis
Atrial Fibrillation - Therapeutics under Development by Companies
Atrial Fibrillation - Therapeutics under Investigation by Universities/Institutes
Atrial Fibrillation - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Atrial Fibrillation - Products under Development by Companies
Atrial Fibrillation - Products under Investigation by Universities/Institutes
Atrial Fibrillation - Companies Involved in Therapeutics Development
ARCA biopharma, Inc.
AstraZeneca Plc
Bristol-Myers Squibb Company
Cardiome Pharma Corp.
Daiichi Sankyo Company, Limited
Dong-A Socio Holdings Co. Ltd.
Gilead Sciences, Inc.
Laboratoires Pierre Fabre SA
Nissan Chemical Industries, Ltd.
OMEICOS Therapeutics GmbH
Otsuka Holdings Co., Ltd.
Xention Limited
Atrial Fibrillation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AFC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-919373 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bucindolol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-373280 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flecainide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIP-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPC-108459 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-023725 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vernakalant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEN-R0702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEND-0103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XENR-0703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XENR-0706 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrial Fibrillation - Dormant Projects
Atrial Fibrillation - Discontinued Products
Atrial Fibrillation - Product Development Milestones
Featured News & Press Releases
May 11, 2016: Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study
May 02, 2016: New drug more effective in treating atrial fibrillation
Mar 31, 2016: Cardiome Announces Publication of Independent Study Comparing BRINAVESS to IBUTILIDE in Patients with Recent-Onset Atrial Fibrillation
Mar 24, 2016: Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA(edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session
Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA
Jan 13, 2016: Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia
Dec 22, 2015: Cardiome Files New Drug Submission Seeking Canadian Approval Of Intravenous Vernakalant
Nov 02, 2015: Daiichi Sankyo, Inc. Announces New Subgroup Analyses of Once-Daily SAVAYSA in Patients with Non-Valvular Atrial Fibrillation Will Be Presented at AHA Scientific Sessions 2015
Nov 02, 2015: OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation
Sep 23, 2015: UK’s NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation
Aug 10, 2015: United Kingdom Department of Health Sets BRINAVESS Pricing
Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China
Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are 'Spoilt for Choice'
Jun 25, 2015: Daiichi Sankyo’s Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE
Jun 12, 2015: Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Atrial Fibrillation, H2 2016
Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Investigation by Universities/Institutes, H2 2016
Atrial Fibrillation - Pipeline by ARCA biopharma, Inc., H2 2016
Atrial Fibrillation - Pipeline by AstraZeneca Plc, H2 2016
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H2 2016
Atrial Fibrillation - Pipeline by Cardiome Pharma Corp., H2 2016
Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H2 2016
Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H2 2016
Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H2 2016
Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H2 2016
Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Atrial Fibrillation - Pipeline by Xention Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Atrial Fibrillation - Dormant Projects, H2 2016
Atrial Fibrillation - Dormant Projects (Contd.1), H2 2016
Atrial Fibrillation - Dormant Projects (Contd.2), H2 2016
Atrial Fibrillation - Dormant Projects (Contd.3), H2 2016
Atrial Fibrillation - Dormant Projects (Contd.4), H2 2016
Atrial Fibrillation - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Atrial Fibrillation, H2 2016
Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

ARCA biopharma, Inc.
AstraZeneca Plc
Bristol-Myers Squibb Company
Cardiome Pharma Corp.
Daiichi Sankyo Company, Limited
Dong-A Socio Holdings Co. Ltd.
Gilead Sciences, Inc.
Laboratoires Pierre Fabre SA
Nissan Chemical Industries, Ltd.
OMEICOS Therapeutics GmbH
Otsuka Holdings Co., Ltd.
Xention Limited
Skip to top


Atrial Fibrillation Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 166 pages
Atrial Fibrillation: Market Research Report US$ 3,950.00 Aug, 2010 · 301 pages

Ask Your Question

Atrial Fibrillation - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: